About Belyntic

Belyntic is an early-stage preclinical biotech company, developing a portfolio of highly effective T cell-inducing vaccines against viral and bacterial infectious diseases.

Pioneering tomorrow’s cures today

Our objective is to supply therapeutic and preventive vaccines to individuals afflicted by infectious diseases or those at significant risk of contracting them. Unlike many other vaccines in progress, our emphasis lies in safely eliciting cellular immune responses via T cells. This approach equips the body with the means to combat existing infections and offer long-term protection against reactivation and reinfection.

While many vaccine candidates currently available or in development prioritize antibodies as the primary components of the humoral immune response, our approach diverges, focusing on unique realms of significance. Centered on T cell-inducing vaccination, our approach aims to combat existing infections and provide long-term protection through the activation of memory T cells.

Focus on latent viral infections

A collaboration with Charité Berlin (Prof. Leif E. Sander)

Cytomegalovirus (CMV)

Our main goal is to develop a new CMV vaccine aimed at safeguarding vulnerable patients, such as solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients, who face considerable risks from CMV reactivation. With our cutting-edge technology, we are committed to protecting the health and improving the quality of life for individuals susceptible to CMV-related complications.

John Cunningham virus (JCV)

Immunocompromised individuals face the risk of latent JCV infection reactivation, leading to progressive multifocal leukoencephalopathy (PML), a potentially fatal brain condition. Current treatment options for PML are limited, resulting in low survival rates and significant brain damage. However, a therapeutic T cell-inducing vaccination offers hope for these patients, potentially easing their condition.

Meet our dedicated team

Get to know the team behind Belyntic’s innovative biotech solutions.

Dr. Oliver Reimann

Co-Managing Director – Technical Lead

Andreas Regnery

Co-Managing Director – Financial Lead